Health Catalyst, Inc. (HCAT) has a consensus analyst rating of Buy, based on 22 analysts covering the stock. Of those, 12 recommend buying, 10 recommend holding, and 0 recommend selling.
The analyst consensus price target for HCAT is $3.00, representing a +167.9% upside from the current price of $1.12. Price targets range from a low of $2.00 to a high of $4.00.
